Cellromax Science Co., Ltd. (KOSDAQ:471820)

Cellromax Science Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	678.33	1,054
Short-Term Investments	2,020	14,767
Trading Asset Securities	5,005	6,910
Cash & Short-Term Investments	7,703	22,732
Cash Growth	-66.11%	-
Accounts Receivable	723.54	531.1
Other Receivables	93.05	110.04
Receivables	816.59	641.14
Inventory	5,684	5,186
Prepaid Expenses	56.6	38.07
Other Current Assets	120.8	105.36
Total Current Assets	14,382	28,702
Property, Plant & Equipment	3,509	3,661
Long-Term Investments	29,184	10,719
Other Intangible Assets	2,801	3,470
Long-Term Accounts Receivable	0	-0
Long-Term Deferred Tax Assets	-	68.46
Other Long-Term Assets	1,032	2,479
Total Assets	50,908	49,100
Accounts Payable	1,609	1,543
Accrued Expenses	494.9	426.72
Current Portion of Leases	209.8	166.9
Current Income Taxes Payable	22.92	562.08
Other Current Liabilities	427.46	456.07
Total Current Liabilities	2,764	3,154
Long-Term Debt	-	983.07
Long-Term Leases	268.03	348.21
Pension & Post-Retirement Benefits	8.34	93.05
Long-Term Deferred Tax Liabilities	949.58	-
Other Long-Term Liabilities	-	-0
Total Liabilities	3,990	4,579
Common Stock	1,177	1,164
Additional Paid-In Capital	7,050	13,152
Retained Earnings	38,211	32,875
Treasury Stock	-2,818	-2,670
Comprehensive Income & Other	3,299	-0
Shareholders' Equity	46,918	44,522
Total Liabilities & Equity	50,908	49,100
Total Debt	477.83	1,498
Net Cash (Debt)	7,226	21,234
Net Cash Growth	-65.97%	-
Net Cash Per Share	635.73	2041.44
Filing Date Shares Outstanding	11.24	11.36
Total Common Shares Outstanding	11.24	11.36
Working Capital	11,618	25,548
Book Value Per Share	4174.41	3920.63
Tangible Book Value	44,117	41,051
Tangible Book Value Per Share	3925.18	3615.03
Land	996.84	996.84
Buildings	2,099	2,099
Machinery	852.71	777.99

Source: S&P Global Market Intelligence. Standard template. Financial Sources.